The Journal of Urology
Volume 183, Issue 3 , Pages 946-951 , March 2010

Initial Prostate Specific Antigen 1.5 ng/ml or Greater in Men 50 Years Old or Younger Predicts Higher Prostate Cancer Risk

Received 26 June 2009

References 

  1. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310
  2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320
  3. National Comprehensive Cancer Network Clinical Practice Guideline in Oncology. Prostate Cancer Early Detection, version V.2.2007. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdfAccessed November 25, 2008
  4. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411
  5. Antenor JA, Han M, Roehl KA, et al. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004;172:90
  6. Loeb S, Nadler RB, Roehl KA, et al. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. J Urol. 2007;177:1745
  7. Lane JA, Howson J, Donovan JL, et al. Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ. 2007;335:1139
  8. Scales CD, Antonelli J, Curtis LH, et al. Prostate-specific antigen screening among young men in the United States. Cancer. 2008;113:1315
  9. Smith CV, Bauer JJ, Connelly RR, et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol. 2000;164:1964
  10. Khan MA, Han M, Partin AW, et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003;62:86
  11. Whittemore AS, Cirillo PM, Feldman D, et al. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol. 2005;174:872
  12. Roobol MJ, Roobol DW, Schroder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? ((ERSPC, section Rotterdam)). Urology. 2005;65:343
  13. Fowler JE, Bigler SA, Lynch C, et al. Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. Cancer. 2001;91:1291
  14. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985
  15. Winter DL, Hanlon AL, Raysor SL, et al. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology. 2001;58:614
  16. Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009;472:439
  17. Schroder FH, Roobol-Bouts M, Vis AN, et al. Prostate-specific antigen-based early detection of prostate cancer–validation of screening without rectal examination. Urology. 2001;57:83

 Supported by Duke University Committee for Urologic Research, Education and Development research funds (LS, CNR, TJP, DMA, and JWM), and Guangzhou First Municipal People's Hospital, Guangzhou Medical College, Guangdong, China (PT).

PII: S0022-5347(09)02910-3

doi: 10.1016/j.juro.2009.11.021

The Journal of Urology
Volume 183, Issue 3 , Pages 946-951 , March 2010

Article Tools

* Image Usage & Resolution